SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-1.1
Date Filed: 2025-08-27
Accession Number: 0001213900-25-081175
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025081175/ea025480001ex1-1_synergy.htm

Chunk 16 of 27
Word Count: 1498
Character Count: 9324

Document Content:

TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, THE REGISTRATION STATEMENT, THE TIME OF SALE DISCLOSURE PACKAGE, ANY PROSPECTUS AND THE FINAL PROSPECTUS. 17. Counterparts. This Agreement may be executed and delivered (including by facsimile transmission or electronic mail) in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall each be deemed to be an original and all such counterparts shall together constitute one and the same instrument. [Signature page follows] If the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between us. Very truly yours, SYNERGY CHC CORP. By: /s/ Jack Ross Name: Jack Ross Title: Chief Executive Officer

Confirmed as of the date first above written

on behalf of itself and as Representative of the
several Underwriters named on Schedule 1 hereto:

BANCROFT CAPITAL, LLC

By:	/s/ Jason Diamond

Name: Jason Diamond

Title: Head of Investment Banking

SCHEDULE I

Underwriter Number of Shares

Bancroft Capital, LLC 1,750,000

SCHEDULE II

Final Term Sheet

Issuer: Synergy CHC Corp. (the “Company”)

Symbol: SNYR

Securities: 1,750,000 shares of common stock, par value $0.00001 per share (the “Common Stock”), of the Company

52,500 shares of Common Stock underlying the Representative Warrants

Public offering price: $2.50 per share of Common Stock

Over-allotment option: 262,500 shares of Common Stock

Underwriting discount: $0.175 per share of Common Stock

Expected net proceeds: Approximately $3.9 million (after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company).

Trade date: August 26, 2025

Settlement date: August 27, 2025

Underwriter: Bancroft Capital, LLC

SCHEDULE III

Free Writing Prospectus

None.

SCHEDULE IV

Written Testing-the-Waters Communications

None.

SCHEDULE V

List of Lock-Up Parties

Jack Ross

Jaime Fickett

Alfred Baumeler

J. Paul SoRelle

Nitin Kaushal

Scott Woodburn

EXHIBIT A

Form of Representative Warrant

THE REGISTERED HOLDER OF THIS SECURITY BY ITS
ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS SECURITY, OR ANY UNDERLYING SECURITIES, EXCEPT AS HEREIN PROVIDED,
AND THE HOLDER OF THIS SECURITY AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHOCATE THIS SECURITY , OR ANY OF THE UNDERLYING
SECURITIES, FOR A PERIOD OF ONE HUNDRED AND EIGHTY (180) DAYS FOLLOWING THE DATE OF THIS SECURITY.

COMMON STOCK PURCHASE WARRANT

For the Purchase of [●] Shares of Common
Stock,

Par Value $0.00001 per Share,

Synergy CHC Corp.

Warrant Shares: [●]

Initial Exercise Date: [●], 2025

THIS CERTIFIES THAT, pursuant to that certain
Underwriting Agreement by and between Synergy CHC Corp., a Nevada corporation (the “Company”) and Bancroft Capital,
LLC dated August [●], 2025 (the “Underwriting Agreement”), Bancroft Capital, LLC (“Holder”)
and its assignees, as registered holders of this purchase warrant (this “Warrant”), is entitled, at any time or from
time to time from [●], 2025 (the “Initial Exercise Date”), the date that is one hundred and eighty (180)
days after the date of the commencement of the sales of the Company’s common stock, $0.0001 par value per share (the “Common
Stock”), and at or before 5:00 p.m., Eastern time, on the applicable expiration date for each portion of this Warrant, as follows:
(i) twenty-five percent (25%) of the Warrant Shares (as defined below) shall expire on the date that is three (3) years from the Effective
Date, (ii) twenty-five percent (25%) of the Warrant Shares shall expire on the date that is four (4) years from the Effective Date, and
(iii) the remaining fifty percent (50%) of the Warrant Shares shall expire on the date that is five (5) years from the Effective Date
(each, a “Termination Date” with respect to the applicable portion of the Warrant), but not thereafter, to subscribe
for, purchase and receive, in whole or in part, up to [●] shares of Common Stock (equal to three (3.0%) percent of the Common Stock
sold in the Offering) (subject to adjustment hereunder, the “Warrant Shares”). If the Termination Date is a day on
which banking institutions are authorized by law to close, then this Warrant may be exercised on the next succeeding day which is not
such a day in accordance with the terms herein. During the period ending on the Termination Date, the Company agrees not to take any action
that would terminate this Warrant. This Warrant is initially exercisable at $[●] per share of Common Stock (110% of the price of
the Common Stock sold in the Offering); provided, however, that upon the occurrence of any of the events specified in Section
3 hereof, the rights granted by this Warrant, including the exercise price per share and the number of shares of Common Stock to be
received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial
exercise price as set forth above or the adjusted exercise price as a result of the events set forth in Section 3 below, depending
on the context.

Section 1. Definitions.

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

“Common Stock
Equivalents” means any securities of the Company that would entitle the holder thereof to acquire shares of Common Stock.

“Effective Date”
means the date of the closing of the Offering pursuant to the Underwriting Agreement.

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

“Securities Act”
means the Securities Act of 1933, as amended.

“Trading Day” means a day on
which the Trading Market is open for trading.

“Trading Market”
means any of the following markets or exchanges on which the shares of Common Stock are listed or quoted for trading on the date in question:
the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange
(or any successors to any of the foregoing).

“Transfer
Agent” means the transfer agent and registrar in respect of the shares of Common Stock.

Capitalized terms used but
not otherwise defined herein shall have the meanings ascribed to such terms in the Underwriting Agreement.

Section 2. Exercise.

Exercise of the purchase rights represented by
this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination
Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered
Holder at the address of the Holder appearing on the books of the Company) of a duly executed copy of the Notice of Exercise Form annexed
hereto. Within two (2) Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price
for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank,
unless the cashless exercise procedure specified in Section 2(b) below is specified in the applicable Notice of Exercise. Notwithstanding
anything herein to the contrary (although the Holder may surrender the Warrant to, and receive a replacement Warrant from, the Company),
the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company
for cancellation within two (2) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of
this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering
the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.
The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise Form within one (1) Trading Day of delivery of such notice. The Holder by acceptance
of this Warrant or any transferee, acknowledges and agrees that, by reason of the provisions of this Section 2, following the purchase
of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less
than the amount stated on the face hereof.

(a) Exercise Price.
The initial exercise price per share of the Common Stock under this Warrant shall be equal to 110% of the initial public offering price,
subject to adjustment under Section 3 (the “Exercise Price”).